Title : Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.

Pub. Date : 2018 Mar

PMID : 29662541






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Cabozantinib is an oral multitargeted tyrosine kinase inhibitor (TKI) that potently inhibits MET and AXL, both associated with poor prognosis in renal cell carcinoma (RCC), next to vascular endothelial growth factor receptor 2, KIT, FLT3 and RET. cabozantinib fms related receptor tyrosine kinase 3 Homo sapiens